FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015926554> ?p ?o ?g. }

• W3015926554 endingPage "858" @default.
• W3015926554 startingPage "853" @default.
• W3015926554 abstract "Bevacizumab treatment is subject to large interpatient variability in efficacy, which may partly be explained by differences in complex bevacizumab pharmacokinetic characteristics that influence bevacizumab exposure. Exposure-response relationships have been identified for other monoclonal antibodies. We aimed to identify possible exposure-survival relationships in bevacizumab-treated patients with metastatic colorectal cancer (mCRC).Patients with mCRC who started first-line bevacizumab-based chemotherapy between July 2012 and July 2014, and from whom serial blood samples and survival were prospectively collected, were included. Follow-up was carried out until July 2018. Total bevacizumab trough concentrations were measured from cycle 2 to cycle 30 of treatment. The receiver operating characteristic (ROC) curve analysis and Cox analysis were used to identify the relationship between concentrations and overall survival (OS). In addition, OS was compared between different trough concentration groups.One hundred fifty-seven blood samples from 46 patients were evaluable for analyses. ROC analysis showed a clear separation in survival based on trough levels (area under the curve = 0.739, p = .009). Cox regression also showed a strong positive correlation between trough levels and survival (p = .0004). Three distinct groups of exposure were identified: low (median trough concentration [Ctm ] ≤41.9 mg/L); medium (Ctm 43-87.2 mg/L) with median OS of 12.8 and 36 months, respectively (p = .0003); and high (Ctm ≥7.9 mg/L), where the majority of patients were still alive 60 months after the initiation of treatment.This study shows that survival was proportional to the magnitude of exposure in patients with mCRC. Further clinical research should focus on clarifying these exposure-outcome relationships in order to optimize dosing.Bevacizumab-based chemotherapy is standard first-line treatment in metastatic colorectal cancer. Moreover, bevacizumab presents complicated pharmacokinetics, and in many cases, clinical outcomes can be highly variable, with some patients responding remarkably well and others not. This study's results show that patients who experienced longer overall survival also had significantly higher exposure to bevacizumab. Therefore, bevacizumab trough concentrations could be used both as a predictive biomarker and as a tool for treatment monitoring and optimization. Finally, the development of validated, rapid, and sensitive assays for bevacizumab concentration measurements in combination with these results may lead to a therapeutic drug monitoring-guided approach in bevacizumab treatment with better clinical outcomes." @default.
• W3015926554 created "2020-04-17" @default.
• W3015926554 creator A5010139507 @default.
• W3015926554 creator A5029346532 @default.
• W3015926554 creator A5072785057 @default.
• W3015926554 creator A5090213991 @default.
• W3015926554 date "2020-04-28" @default.
• W3015926554 modified "2023-10-01" @default.
• W3015926554 title "Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer" @default.
• W3015926554 cites W1667033073 @default.
• W3015926554 cites W1915689252 @default.
• W3015926554 cites W1996684935 @default.
• W3015926554 cites W2005348280 @default.
• W3015926554 cites W2023187096 @default.
• W3015926554 cites W2033958365 @default.
• W3015926554 cites W2041444113 @default.
• W3015926554 cites W2043021219 @default.
• W3015926554 cites W2047727316 @default.
• W3015926554 cites W2062756251 @default.
• W3015926554 cites W2064651476 @default.
• W3015926554 cites W2079852644 @default.
• W3015926554 cites W2083749767 @default.
• W3015926554 cites W2095572961 @default.
• W3015926554 cites W2112196468 @default.
• W3015926554 cites W2125447919 @default.
• W3015926554 cites W2129331774 @default.
• W3015926554 cites W2142616277 @default.
• W3015926554 cites W2156599794 @default.
• W3015926554 cites W2161482321 @default.
• W3015926554 cites W2168750246 @default.
• W3015926554 cites W2172181172 @default.
• W3015926554 cites W2235523093 @default.
• W3015926554 cites W2416696399 @default.
• W3015926554 cites W2423724319 @default.
• W3015926554 cites W2560322684 @default.
• W3015926554 cites W2899649326 @default.
• W3015926554 cites W2909588705 @default.
• W3015926554 cites W4289258260 @default.
• W3015926554 cites W4376848628 @default.
• W3015926554 doi "https://doi.org/10.1634/theoncologist.2019-0835" @default.
• W3015926554 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7543296" @default.
• W3015926554 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32272489" @default.
• W3015926554 hasPublicationYear "2020" @default.
• W3015926554 type Work @default.
• W3015926554 sameAs 3015926554 @default.
• W3015926554 citedByCount "18" @default.
• W3015926554 countsByYear W30159265542020 @default.
• W3015926554 countsByYear W30159265542021 @default.
• W3015926554 countsByYear W30159265542022 @default.
• W3015926554 countsByYear W30159265542023 @default.
• W3015926554 crossrefType "journal-article" @default.
• W3015926554 hasAuthorship W3015926554A5010139507 @default.
• W3015926554 hasAuthorship W3015926554A5029346532 @default.
• W3015926554 hasAuthorship W3015926554A5072785057 @default.
• W3015926554 hasAuthorship W3015926554A5090213991 @default.
• W3015926554 hasBestOaLocation W30159265541 @default.
• W3015926554 hasConcept C10515644 @default.
• W3015926554 hasConcept C112705442 @default.
• W3015926554 hasConcept C121608353 @default.
• W3015926554 hasConcept C126322002 @default.
• W3015926554 hasConcept C143998085 @default.
• W3015926554 hasConcept C2776694085 @default.
• W3015926554 hasConcept C2777802072 @default.
• W3015926554 hasConcept C2910800852 @default.
• W3015926554 hasConcept C50382708 @default.
• W3015926554 hasConcept C526805850 @default.
• W3015926554 hasConcept C71924100 @default.
• W3015926554 hasConcept C76318530 @default.
• W3015926554 hasConcept C90924648 @default.
• W3015926554 hasConceptScore W3015926554C10515644 @default.
• W3015926554 hasConceptScore W3015926554C112705442 @default.
• W3015926554 hasConceptScore W3015926554C121608353 @default.
• W3015926554 hasConceptScore W3015926554C126322002 @default.
• W3015926554 hasConceptScore W3015926554C143998085 @default.
• W3015926554 hasConceptScore W3015926554C2776694085 @default.
• W3015926554 hasConceptScore W3015926554C2777802072 @default.
• W3015926554 hasConceptScore W3015926554C2910800852 @default.
• W3015926554 hasConceptScore W3015926554C50382708 @default.
• W3015926554 hasConceptScore W3015926554C526805850 @default.
• W3015926554 hasConceptScore W3015926554C71924100 @default.
• W3015926554 hasConceptScore W3015926554C76318530 @default.
• W3015926554 hasConceptScore W3015926554C90924648 @default.
• W3015926554 hasIssue "10" @default.
• W3015926554 hasLocation W30159265541 @default.
• W3015926554 hasLocation W30159265542 @default.
• W3015926554 hasLocation W30159265543 @default.
• W3015926554 hasOpenAccess W3015926554 @default.
• W3015926554 hasPrimaryLocation W30159265541 @default.
• W3015926554 hasRelatedWork W1964567729 @default.
• W3015926554 hasRelatedWork W2051540233 @default.
• W3015926554 hasRelatedWork W2098707609 @default.
• W3015926554 hasRelatedWork W2122166711 @default.
• W3015926554 hasRelatedWork W2145753255 @default.
• W3015926554 hasRelatedWork W2339289555 @default.
• W3015926554 hasRelatedWork W2517493814 @default.
• W3015926554 hasRelatedWork W3017010154 @default.
• W3015926554 hasRelatedWork W3203896279 @default.
• W3015926554 hasRelatedWork W4212844545 @default.

• next